Page 11 - reflections_newsletter_June8_2022

REFLECTIONS dae mia
Dyslipidaemia Global Newsletter #2
aim ead
Dyslipi

12. Clinical efficacy and safety outcomes of bempedoic acid for LDL-C lowering therapy in patients at high Dys lipi
cardiovascular risk: A systematic review and meta-analysis. Lin Y, et al. BMJ Open. 2022 Feb 24;12(2):e048893.

13. Effect of alirocumab added to high-Intensity statin therapy on coronary atherosclerosis in patients with acute
myocardial infarction: The PACMAN-AMI randomized clinical trial. Räber L, et al. JAMA. 2022 Apr 3. doi: 10.1001/
jama.2022.5218. Online ahead of print.

14. Baseline low-density lipoprotein cholesterol and clinical outcomes of combining ezetimibe with statin therapy in
IMPROVE-IT. Oyama K, et al. J Am Coll Cardiol. 2021;78(15):1499-1507.

ACRONYMS:
ACC, American College of Cardiology; ACS, acute coronary syndrome; AHA, American Heart Association; ASCVD, atherosclerotic
cardiovascular disease; CAC, coronary artery calcium; CCTA, coronary computed tomography angiography; CETP, cholesteryl
ester transfer protein; CHD, coronary heart disease; CV, cardiovascular; CVD, cardiovascular disease; DM, diabetes mellitus;
EAS, European Atherosclerosis Society; ESC, European Society of Cardiology; FH, familial hypercholesterolaemia; HC,
hypercholesterolaemia; HDL-C, high-density lipoprotein cholesterol; HF, heart failure; HMG-CoA, 3-hydroxy-3-methylglutaryl
coenzyme A; IVUS, intravascular ultrasound; LDL-C, low-density lipoprotein cholesterol; MRI, magnetic resonance imaging; NIRS,
near infrared spectroscopy; OCT, optical coherence tomography; OMT, optimal medical therapy; PCSK9, proprotein convertase
subtillisin/kexin type 9 inhibitors; PET, positron emission tomography; RF, risk factor; siRNA, small interfering ribonucleic acid; TG,
triglycerides.

TABLE OF CONTENTS Learn more at: www.serviercardiomedicalhub.com